Skip to main content

Military Health System

Development of WRAIR’s Pan-Coronavirus Vaccine Shows Promise

Image of A vial of spike ferritin nanoparticle WRAIR's COVID-19 vaccine. A vial of spike ferritin nanoparticle (SpFN), WRAIR’s COVID-19 vaccine. Built on a ferritin platform, the vaccine offers a flexible approach to targeting multiple variants of the virus that causes COVID-19 and potentially other coronaviruses as well (Photo by: Mike Walters, Walter Reed Army Institute of Research).

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

A series of recently published preclinical study results show that the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland not only elicits a potent immune response but may also provide broad protection against SARS-CoV-2 variants of concern as well as other coronaviruses.

Scientists in WRAIR's Emerging Infectious Diseases Branch (EIDB) developed the SpFN nanoparticle vaccine, based on a ferritin platform, as part of a forward-thinking "pan-SARS" strategy that aims to address the current pandemic and acts as a first line of defense against variants of concern and similar viruses that could emerge in the future.

"The accelerating emergence of human coronaviruses throughout the past two decades and the rise of SARS-CoV-2 variants, including most recently Omicron, underscore the continued need for next-generation preemptive vaccines that confer broad protection against coronavirus diseases," said Dr. Kayvon Modjarrad, director of the Emerging Infectious Diseases Branch at WRAIR, co-inventor of the vaccine and the Army lead for SpFN. "Our strategy has been to develop a 'pan-coronavirus' vaccine technology that could potentially offer safe, effective and durable protection against multiple coronavirus strains and species."

Pre-clinical studies published today in Science Translational Medicine indicate that the SpFN vaccine protects non-human primates from disease caused by the original strain of SARS-CoV-2 and induces highly-potent and broadly-neutralizing antibody responses against major SARS-CoV-2 variants of concern including the SARS-CoV-1 virus that emerged in 2002.

SpFN entered Phase 1 human trials in April 2021. Early analyses, expected to conclude this month, will provide insights into whether SpFN's potency and breadth, as demonstrated in preclinical trials, will carry over into humans. The data will also allow researchers to compare SpFN's immune profile to that of other COVID-19 vaccines already authorized for emergency use.

"This vaccine stands out in the COVID-19 vaccine landscape," Modjarrad said. "The repetitive and ordered display of the coronavirus spike protein on a multi-faced nanoparticle may stimulate immunity in such a way as to translate into significantly broader protection."

WRAIR developed a secondary candidate vaccine, a SARS-CoV-2 Spike Receptor-Binding Domain Ferritin Nanoparticle (RFN) vaccine, which targets a smaller part of the coronavirus Spike protein than the SpFN vaccine. Results from a study, published recently in the Proceedings of the National Academy of Sciences, show that this vaccine potentially offers similar protection against an array of SARS-CoV-2 variants and SARS-CoV-1.

"The RFN vaccine candidate is more compact and has some natural advantages as we try to increase the immune response against multiple coronaviruses using a single vaccine platform, so it is still under consideration as part of our pan-coronavirus vaccine development pipeline," said Dr. Gordon Joyce, WRAIR structural biologist and vaccine co-inventor.

"The threat from COVID-19 continues as it evolves, and eventually there will be other emerging disease threats," said Dr. Nelson Michael, director of the Center for Infectious Diseases Research at WRAIR. "Our investment in developing a next generation vaccine is an important step towards getting ahead of COVID-19 and future disease threats."

You also may be interested in...

Prevent the Spread of Influenza and COVID-19 Viruses Within Your Community

Article
10/11/2022
A person getting an injection on their arm.

As families return from summer vacation and students return to school, the influenza (flu) season is approaching while the COVID-19 pandemic is still on-going.

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts | Immunizations | Coronavirus and the COVID-19 Vaccine | Seasonal Influenza Vaccine Toolkit

COVID-19: Bottom Line on Boosters

Infographic
9/19/2022
COVID-19: Bottom Line on Boosters

Bottom Line on Boosters: Stay up to date!

Recommended Content:

Coronavirus and the COVID-19 Vaccine

DHA Form 207: COVID-19 Vaccine Screening and Immunization Document v22

Form/Template
9/9/2022

The purpose of this form is to determine if the COVID-19 vaccine can be administered to the patient. (v22, Sept. 2022)

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Immunization Healthcare Division | COVID-19 Vaccine Efforts | COVID-19 Information for Military Treatment Facility Directors | Coronavirus

Ramstein Now Offers Novavax Vaccine

Article Around MHS
9/8/2022
Military medical gives Soldier a COVID-19 vaccine

The 86th Medical Group is now offering the Novavax COVID-19 vaccine, which has been authorized for emergency use by the U.S. Food and Drug Administration, to members 18 years and older in the Kaiserslautern Military Community.

Recommended Content:

Immunization Healthcare Division | COVID-19 Vaccine Efforts | Immunizations | Coronavirus

Novavax COVID-19 Vaccine Now Available for 12 to 17 Year-Olds

Article
8/30/2022
Air Force Staff. Sgt. fills a syringe with a COVID-19 vaccine at Ramstein Air Base, Germany.

Novavax COVID-19 Vaccine is Available for Those 12 Years' Old and Above

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vaccine Efforts

New COVID-19 Boosters Against Subvariants Coming Soon

Article
8/29/2022
Marine on right gets a COVID-19 booster vaccination from a nursing student on his left.

Brooklyn Marine gets COVID-19 booster vaccination.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vaccine Efforts

How to Get Your Kids Up to Date on Vaccinations

Article
8/25/2022
Child wearing a mask getting the COVID-19 vaccine

Resources to help you get and keep your child’s immunizations up to date in time for back to school.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Back to School | Immunization Healthcare Division

Consolidated Department of Defense Coronavirus Disease 2019 Force Health Protection Guidance

Policy

Consolidates and updates the Department’s guidance regarding vaccination verification, vaccination status, COVID-19 testing, surveillance and screening testing, personnel protection on-site mask requirements, (e.g., DHA military medical treatment facilities, meetings, travel), and the protection of personally identifiable information.

COVID-19 Novavax Vaccine

Infographic
8/18/2022
COVID-19 Novavax Vaccine

The Novavax COVID-19 Vaccine, Adjuvanated includes two doses, 21 days apart. Remember to mark your calendar and schedule time for your second dose.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Types of COVID-19 Vaccines

COVID-19 Vaccines

Infographic
8/18/2022
COVID-19 Vaccines

How COVID-19 Vaccines Work – There are three types of vaccines currently available: mRNA, subunit protein, and viral vector. Pfizer and Moderna are mRNA vaccine. Novavax is a subunit protein vaccine. Janssen is a viral vector vaccine. All products resemble a virus for the immune system to fight.

Recommended Content:

Coronavirus and the COVID-19 Vaccine

COVID-19 Moderna Vaccine

Publication
8/17/2022

Moderna and mRNA vaccines are available. Moderna includes two doses, 28 days apart.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Get to Know the COVID-19 Vaccines | Types of COVID-19 Vaccines | Coronavirus & the MHS Response

COVID-19 Pfizer Vaccine

Publication
8/17/2022

Pfizer mRNA vaccines are available. Pfizer includes two doses, 21 days apart.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Get to Know the COVID-19 Vaccines | Types of COVID-19 Vaccines | Coronavirus & the MHS Response

COVID-19 Moderna and Pfizer Vaccines

Publication
8/17/2022

Moderna and Pfizer mRNA vaccines are available. Moderna includes two doses, 28 days apart. Pfizer includes two doses, 21 days apart. Remember to mark your calendar and schedule time for your second dose

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Get to Know the COVID-19 Vaccines | Types of COVID-19 Vaccines | Coronavirus & the MHS Response

Learn the Most Recent Age Requirements for COVID-19 Vaccines and Boosters

Article
8/10/2022
A man fist bumps a child.

The best way to prevent the spread of COVID-19 is to get your vaccines and booster shots.

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

Telemedicine Privilege by Proxy Expands Access to MHS Care

Article
8/10/2022
Infographic featuring Lt Col Legault

MHS has Telemedicine Privilege by Proxy: A fast, efficient process that enables providers to file one application and get permission to virtually treat patients anywhere in the MHS.

Recommended Content:

Coronavirus & the MHS Response | Telehealth Program
<< < 1 2 3 4 5  ... > >> 
Showing results 16 - 30 Page 2 of 31
Refine your search
Last Updated: December 28, 2021
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery